Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Docetaxel and Cisplatin in High-Risk NSCLC
NCT00995761Phase 2Completed
- Sponsor
- Gyeongsang National University Hospital
- Start
- Oct 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Gyeongsang National University Hospital. Primary endpoints: Response Rate and Safety and Toxicity. Started Oct 2009; status: completed.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00995761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995761.